Drug Profile
Research programme: small molecule therapeutics - ChemDiv/Eli Lilly and Company
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator ChemDiv; Eli Lilly and Company
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified